Switch theme
Sign up to access all valuation multiples
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
2002
20
Last FY Revenue $2.6M
Last FY EBITDA $9.4M
$7.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Pharmena achieved revenue of $2.6M and an EBITDA of $9.4M.
Pharmena expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharmena valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 59% | XXX | XXX | XXX |
| EBITDA | XXX | $9.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 361% | XXX | XXX | XXX |
| EBIT | XXX | -$0.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -23% | XXX | XXX | XXX |
| Net Profit | XXX | $7.7M | XXX | XXX | XXX |
| Net Margin | XXX | 294% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pharmena's stock price is PLN 4 (or $1).
Pharmena has current market cap of PLN 39.0M (or $10.3M), and EV of PLN 28.3M (or $7.5M).
See Pharmena trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.5M | $10.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pharmena has market cap of $10.3M and EV of $7.5M.
Pharmena's trades at 2.9x EV/Revenue multiple, and 0.8x EV/EBITDA.
Equity research analysts estimate Pharmena's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharmena's P/E ratio is not available.
See valuation multiples for Pharmena and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.3M | XXX | $10.3M | XXX | XXX | XXX |
| EV (current) | $7.5M | XXX | $7.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -12.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmena's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Pharmena's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharmena's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharmena and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 361% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharmena acquired XXX companies to date.
Last acquisition by Pharmena was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharmena acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pharmena founded? | Pharmena was founded in 2002. |
| Where is Pharmena headquartered? | Pharmena is headquartered in Poland. |
| How many employees does Pharmena have? | As of today, Pharmena has 20 employees. |
| Is Pharmena publicy listed? | Yes, Pharmena is a public company listed on WAR. |
| What is the stock symbol of Pharmena? | Pharmena trades under PHR ticker. |
| When did Pharmena go public? | Pharmena went public in 2008. |
| Who are competitors of Pharmena? | Similar companies to Pharmena include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Pharmena? | Pharmena's current market cap is $10.3M |
| Is Pharmena profitable? | Yes, Pharmena is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
